What Does Molecular Residual Disease Mean?

Molecular residual disease, usually shortened to MRD, is not loose marketing language. The Food and Drug Administration built a whole guidance around it. The final document is titled "Use of Circulating Tumor DNA for Curative-Intent Solid Tumor Drug Development." It came from FDA's Oncology Center of Excellence and became final in November 2024.

If you want to know what the term means in your report, that document is the plainest authority available.

FDA defines circulating tumor DNA, or ctDNA, as "tumor-derived fragmented DNA shed into a patient's bloodstream that is not associated with cells."

Two words carry the weight. Fragmented, because tumor cells that die release short broken pieces of DNA, not whole genomes. Not associated with cells, because the test looks at DNA floating free in plasma, not DNA inside circulating cells. The lab spins your blood, keeps the liquid, and hunts for those fragments.

The timing is the definition. In early-stage disease, ctDNA found after definitive local therapy, systemic therapy, or both is what FDA calls MRD. The surgery is done. The scans are clean. And there are still tumor fragments in the plasma.

FDA summarises the evidence carefully: "Multiple small studies have suggested that residual ctDNA detecting molecular residual disease (MRD) after surgery or completion of standard systemic therapy confers a poor prognosis and selects a population at high risk of relapse."

That sentence is the reason anyone orders this test. Note how hedged it is. FDA adds that the evidence for clinical validity and usefulness "varies across solid tumor malignancies, patient populations, and testing modalities." A poor prognosis is not the same as a proven benefit from acting on it.

FDA describes two designs, and knowing which one you got changes how to read your result.

Tumor-informed. FDA says these are "constructed by sequencing the tumor and then selecting a set of variants to follow." Your own tumor tissue is sequenced first. The lab builds a custom panel aimed at your specific mutations, then watches your blood for exactly those. FDA notes the strength is higher specificity. The costs are lag time, because tissue must be sequenced first, and a sensitivity that depends on where the cut-off is set.

Tumor-naive. FDA calls these "generic panels that are not informed by sequencing or by specific mutations known to be present in the primary tumor." They test everyone against the same fixed list. FDA notes the advantage is a "faster turn-around time." The risk is that your tumor's markers may simply not be on the panel.

Neither is better in the abstract. Ask which one was run, and whether your tumor tissue was sequenced for it.

FDA recommends that "a baseline pre-treatment blood sample should be collected to allow for consideration of the impact of variation in tumor shedding rates."

Tumors shed at wildly different rates. A tumor that sheds very little can produce a negative result while cancer is still present. Without a before picture, nobody can tell a true clearance from a tumor that was always quiet in the blood. FDA also asks that "all sites in the study should follow standardized protocols for sample collection, storage, and processing and handling," because handling changes results.

On the assay itself, FDA expects validation of "sensitivity, specificity, accuracy, precision, and other relevant performance characteristics," and states that "the cut-off should be prespecified and optimized to minimize misdiagnosis." A detected or not detected line is a chosen threshold, not a law of nature.

This is the part most articles skip. As of the November 2024 final guidance, ctDNA-based MRD is not an accepted surrogate endpoint for drug approval. FDA's wording: "Although not currently validated for use, changes in ctDNA in response to a drug may have the potential to be used as an early endpoint to support drug approval."

FDA asks for more data from prospective randomized trials that build ctDNA into their endpoints, plus analyses linking ctDNA clearance to disease-free and overall survival.

So the honest status is this. Detectable MRD is a strong risk marker. Whether changing your treatment because of it makes you live longer is being tested right now, cancer by cancer.

FDA lists concrete roles in trial design: selecting patients by molecular alteration, enriching a study with high-risk patients, escalating or de-escalating treatment, finding early signals in small studies, and picking a dose for later studies.

Notice that most of these are ways to sort people, not ways to treat them. If your result is being used to decide on more chemotherapy, or on stopping early, ask whether that decision comes from a trial protocol, a guideline, or a judgment call.

Blood cancers used the initials first, for minimal or measurable residual disease. That version counts leukemia cells left in the marrow after treatment, usually by flow cytometry or by sequencing immune receptor genes. It is far more established.

The National Cancer Institute captures its power in one line about childhood acute lymphoblastic leukemia. Genetic findings combined with MRD results "can define subsets of ALL with EFS rates exceeding 95% and, conversely, subsets with EFS rates of 50% or lower." EFS means event-free survival, the share of children alive with no relapse or second cancer.

Same initials, different test, different maturity of evidence. If your report says MRD, check which one you are reading.

Was my test tumor-informed or tumor-naive? Was my tumor tissue sequenced to build it? Was a baseline sample drawn before treatment? How many days after surgery was this blood taken? What is the cut-off this lab uses for detected? If it is detected, what specifically would we do differently, and is that from a trial, a guideline, or a judgment? If it is not detected, does that change my scan schedule at all? Is there a clinical trial that would use this result?

See the report hub, the report decoder, and Biomarker Testing.

• https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-circulating-tumor-deoxyribonucleic-acid-early-stage-solid-tumor-drug-development-guidance
• https://www.fda.gov/media/183874/download
• https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq